

1 **Title:** Susceptibility to monkeypox virus infection: seroprevalence of orthopoxvirus in 4
2 population samples; France, Bolivia, Laos and Mali.

3 **Short title (for the running head):** seroprevalence of orthopoxvirus

4 **Author list:** Léa Luciani, Nathanaël Lapidus, Abdennour Amroun, Alessandra Falchi,
5 Chanthala Souksakhone, Mayfong Mayxay, Audrey Dubot-Pérès, Paola Mariela Saba
6 Villarroel, Issa Diarra, Ousmane Koita, Pierre Gallian, Xavier de Lamballerie

7 **Author affiliations:**

8
9 Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille,
10 France (L. Luciani, A. Amroun, A. Dubot-Pérès, P.M. Saba Villarroel, A. Dubot Pérès, I.
11 Diarra, P. Gallian, X. de Lamballerie);
12 Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique
13 IPLESP, AP-HP.Sorbonne Université, Public Health Department, Saint-Antoine Hospital,
14 F75012 Paris, France (N. Lapidus);
15 Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte,
16 France (A. Falchi);
17 National Blood Transfusion Centre, Lao Red Cross, Vientiane, Lao PDR (C. Souksakhone) ;
18 Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory,
19 Mahosot Hospital, Vientiane, Lao PDR (M. Mayxay, A. Dubot Pérès)
20 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
21 University of Oxford, Oxford, UK (M. Mayxay, A. Dubot Pérès)
22 Institute of Research and Education Development (IREDE), Ministry of Health, Vientiane, Lao
23 PDR. (M. Mayxay)
24 University of Health Sciences, Ministry of Health, Vientiane, Lao PDR (M. Mayxay)
25 Laboratory of Applied Molecular Biology, Faculty of Pharmacy, University of Sciences,
26 Techniques and Technologies of Bamako, Bamako, Mali (I. Diarra, O. Koita);
27 Établissement Français du Sang, La Plaine Saint Denis, France (P. Gallian)

28

29 **Corresponding author:** Léa Luciani (lea.luciani@univ-amu.fr)

30 **Article summary line:** Seroprevalence of orthopoxvirus tested on 4 continents is very low,
31 even for people born before the eradication of smallpox, making populations vulnerable to the
32 emergence of zoonotic orthopoxviruses such as monkeypox virus.

33 **Key words:** vaccinia virus, cowpox virus, monkeypox virus, seroprevalence

34 **Word count:** 3154

35

36

37

38 **Abstract**

39 Europe is experiencing an epidemic of monkeypox virus against a background of
40 limited knowledge of population immunity to orthopoxviruses. We tested antibodies
41 neutralizing vaccinia virus in blood samples from Bolivia (n=601), Laos (n=657), Mali
42 (n=255) and France (n=4876). We also tested neutralization of cowpox virus in 4448 French
43 samples, which confirmed extensive cross-immunity between both viruses. Using a cut-off
44 titer of 20, seroprevalence is <1% in Bolivia, <5% in Laos (mainly related to vaccination in
45 the elderly), 17.25% in Mali (related to both smallpox vaccination and the likely natural
46 circulation of orthopoxviruses). In France, neutralizing antibodies are found (but at low
47 prevalence) in age groups supposed to be vaccinated, suggesting both decrease in antibody
48 titer in vaccinated individuals and decline in smallpox vaccine compliance before the end of
49 compulsory vaccination. We conclude that the populations tested in Europe, Africa, Asia and
50 South-America are massively susceptible to orthopoxvirus (*e.g.* monkeypox) infections.

51

52

53 **Introduction**

54 In the context of the emergence of monkeypox virus (MPXV) infections, it is
55 legitimate to question the immunity of populations to viruses of the genus *Orthopoxvirus*, to
56 which MPXV, smallpox virus, and vaccinia virus belong. There is a broad cross-immunity
57 between the viruses of this genus, which allowed the use of vaccinia virus as a vaccine to
58 prevent smallpox and which today leads to the use of a vaccinia-derived vaccine to prevent or
59 mitigate MPXV infections.

60 Since 1980, with the cessation of smallpox vaccination, the immunity of the world
61 population against orthopoxviruses has decreased and this has been associated in young
62 populations with the emergence of zoonotic orthopoxviruses with extended host specificity.
63 This is the case of MPXV, which has been responsible for epidemic episodes in Africa (1–3)
64 (which is its original territory of widespread) but also for cases outside this continent(4,5).
65 This is also the case for buffalopox virus(6–8) and camelpox virus(8–10) in Asia and for
66 Cowpox virus, which is ubiquitous(11–13). There is a clear risk that these orthopoxvirus
67 emergence events will become more and more common due to increased travel and trade,
68 ecosystem change, and altered biodiversity and climate(14–16). Since the eradication of
69 smallpox in 1980, work on orthopoxviruses in human medicine has gradually declined.
70 However, in the early 2000's much attention has been paid to the bioterrorism risk associated
71 with smallpox(17–19). This has led to attempts to assess the susceptibility of the general
72 population to smallpox attacks(18), which have generally been based on estimates of
73 smallpox vaccination coverage. In France, Santé Publique France (the French Institute of
74 Public Health) published a report in 2001 based on data from INSEE (National Institute of
75 Statistics and Economic Studies) and Inserm (National Institute of Health and Medical
76 Research), which estimated vaccination coverage in the French population close to 0% for
77 persons born after 1979, 50% for those born between 1972 and 1978, 65% for those born

78 between 1966 and 1971 and 90% for those born prior to 1966(20). As in most developed
79 countries, the strategy to fight smallpox in France has been based on systematic and
80 mandatory vaccination of children. Vaccination consisted in two injections, the first at the age
81 of one and the second usually around the age of 11. It was mandatory from 1902 to 1978
82 (until 1984 for the booster). However, for many resource-limited countries, routine
83 vaccination of the population was difficult to implement, and the WHO shifted in the 1960s to
84 a containment strategy of case identification, isolation, and widespread vaccination of
85 contacts. As is well known, this strategy has been successful in eradicating smallpox(21), but
86 the vaccination coverage of the general population in these countries (which confers potential
87 cross-immunity to other orthopoxviruses) is therefore likely to be lower than in countries
88 where routine vaccination has been organized.

89 In this article, we present a large-scale epidemiological study based on the detection of
90 antibodies neutralizing the vaccinia virus and the cowpox virus. We tested ~6500 persons
91 from four countries of different continents: France France and three low-income countries:
92 Laos, Mali and Bolivia. In the current context of MPXV dissemination, these data provide a
93 recent demographic overview of orthopoxviruses seroprevalence and allow assessment of the
94 susceptibility of relevant populations to infection by this group of viruses.

95 **Materials and methods**

96 *Study population and ethical approval*

97 We investigated four different populations from France, Bolivia, Laos and Mali. All of them
98 were tested for the presence of antibodies neutralizing the vaccinia virus. In addition, a large
99 part of the French population was tested for the presence of antibodies neutralizing the
100 cowpox virus.

101 (i) The French population included 4876 voluntary - unpaid - blood donors, whose serum
102 samples were collected in 2012, 2013, and 2019 from four regions of metropolitan France:
103 Auvergne-Loire (n=837), Corsica (n=596), Midi-Pyrénées (n=1738), and Provence-Alpes-
104 Côte d'Azur (PACA) (n=1705). Donors provided signed informed consent for the use of their
105 blood samples for non-therapeutic research purposes. They completed a questionnaire that
106 included year of birth, gender, and detailed information about their lifestyle, environment
107 (home and workplace), and exposure to zoonotic diseases(22).

108 (ii) The Bolivian population included 601 voluntary, unpaid, blood donors(23), whose serum
109 samples were collected in 2017 among the main cities (urban environment) of 5 departments:
110 Santa Cruz de la Sierra (n=165) and Beni (n=102) (tropical climate); Cochabamba (n=151),
111 Tarija (n=23) and La Paz (n=160) (colder subtropical climate in the highlands). This study
112 was approved by the ethics committee of the Medical College of Santa Cruz and donors
113 provided signed informed consent for research use of their blood samples. The information
114 collected included the year of birth, sex, city of residence and occupation.

115 (iii) For Laos, collection of blood samples from 657 blood donors took place in the capital
116 city of Vientiane in 2003, 2004, 2015 and 2018. Donors provided signed informed consent for
117 research use of their blood samples and the study was approved by the Lao National Health
118 Research Ethics Committee and the Oxford Tropical Research Ethics Committee. The
119 information collected was limited to year of birth and gender.

120 (iv) In Mali, 257 blood samples were collected in 2019 in the villages of Leba, Tliemba,
121 Soloba, Bougoudale and Komana for a baseline study of health indicators in the villages of
122 the Komana gold mine (tropical forest area). Participants provided informed consent for
123 research use of their blood samples and the study was approved by the ethics committee of the

124 National Institute for Public Health Research in Mali. The information collected was limited
125 to year of birth and gender.

126 *Seroneutralization techniques*

127 We used the Western Reserve vaccinia strain and the Compiègne strain of cowpox
128 virus (isolated in 2009 from a human cutaneous lesion following transmission from domestic
129 rats)(24). Both strains were grown on Vero cells (Eagle's Minimum Essential medium with
130 1% Penicillin-Streptomycin, 1% Glutamine and 10% foetal calf serum, 37°C with 5% CO₂).
131 Virus productions used for the sero-neutralization assay were optimized to obtain low and
132 similar ratios of non-infectious particles to infectious particles. For vaccinia virus we used a
133 culture supernatant harvested at D6 titrating to 1.04×10^9 genome copies/mL and 1.67×10^6
134 TCID₅₀/mL (ratio genome copies/TCID₅₀=624). For cowpox virus, we used an early
135 supernatant collected at D2 titrating to 6.82×10^7 genome copies/mL and 1.08×10^5
136 TCID₅₀/mL (ratio=613). Aliquots for individual experiments were prepared with 15mM
137 HEPES buffer and frozen at -80°C.

138 The same seroneutralization protocol was used for both viruses. Dilutions of sera were
139 performed in Eagle's Minimum Essential medium with 1% Penicillin-Streptomycin in a 96-
140 well format using an epMotion® 5075 (Eppendorf) working station. 50µL of dilution were
141 mixed with the same volume of virus (50 TCID₅₀/well) to produce final dilutions of 1:20,
142 1:40, 1:80 and 1:160. The plates were briefly centrifuged (300 rpm for 2 minutes) and
143 incubated for 1 hour at 37°C. The serum/virus mixture was then plated into a cell culture 96-
144 well plates containing confluent Vero cells and 100µL of culture medium (Eagle's Minimum
145 Essential medium with 1% Penicillin-Streptomycin, 1% Glutamine and 10% Fetal Calf
146 Serum). Culture plates were incubated at 37°C under 5% CO₂ for 4 days and included positive

147 (serum of a donor multivaccinated with the Lister strain, supplied by the French National
148 Reference Centre for Orthopoxviruses(25)).

149 Cytopathic effects (CPE) was observed at day 4 post infection. Pictures were obtained
150 using the Cytation® (BioTek. Vermont, USA) or IncuCyte® (Sartorius. Gottingen, Germany)
151 readers for subsequent analysis. Each sample was assigned a result: negative (default value:
152 1:10), or positive at 1:20, 1:40, 1:80 or 1:160 (corresponding to the highest dilution with no
153 CPE)).

154 *Statistics*

155 The distribution of serological titers and the proportion of positives and negatives were
156 compared between decades of birth, regions or gender using the Mann-Whitney and Fisher
157 tests, respectively.

158 The correlation between the anti-vaccinia and anti-cowpox neutralization titers was
159 evaluated by a Spearman coefficient. Comparisons of distributions according to serological
160 status were performed by Mann-Whitney tests for quantitative variables and Fisher tests for
161 categorical variables. Seroprevalence was compared between each pair of regions by a Fisher
162 test (without correction for test multiplicity). Factors associated with the serological titer were
163 sought in univariate analysis and then after adjustment for year of birth by a parametric model
164 based on the hypothesis of a lognormal distribution of titers and taking into account the
165 interval censoring of serological titers(26). For the French population, the covariates studied
166 were the following: gender, marital status, type of occupation, level of education, number of
167 people in the household, household income, general health status, travel outside Europe, type
168 of housing, time spent outdoors, air conditioning, use of mosquito nets, presence of
169 garden/terrace/balcony and swimming pool, rurality of the dwelling, proximity to shops, the
170 presence of a pond or marsh nearby, contact with domestic or farm animals, exposure to

171 mosquitoes and other biting insects and ticks, frequency of bites and protection used, type of
172 water supply, contact with sewage, water consumption, contact with domestic or farm
173 animals, hunting activity, type of meat consumed and cooking.

174 All tests were two-tailed at the 0.05 significance level.

175

176 **Results**

177 *Antibodies neutralizing the vaccinia virus*

178 Results for antibodies neutralizing the vaccinia virus in the different populations
179 (Bolivia, Laos, Mali and France) are presented in Table 1. Overall seroprevalence was
180 calculated for samples with a titer ≥ 40 (ThT40) or with a titer ≥ 20 (ThT20) (see discussion).

181 *Cross immunity between vaccinia and cowpox virus*

182 In the French population, 4448 samples from four regions had sufficient volumes to be
183 tested for both vaccinia and cowpox viruses; 4391 (98.8%) had similar antibody titers for both
184 viruses (same titer ± 1 dilution). Details are presented in Table 2. The correlation coefficient
185 (Spearman) between the two serologies was estimated at 0.68, which supports the hypothesis
186 of a high correlation between these titers.

187 *Prevalence of antibodies neutralizing orthopoxviruses in French populations:*
188 *epidemiological data by age, gender and region*

189 Among the 4448 samples tested for both vaccinia and smallpox virus, sex ratio M/F
190 was 1.17 and mean year of birth was 1966 ± 13 years). Given the difference observed
191 between the seroprevalence values calculated using a threshold titer at 20 (ThT20) or 40
192 (ThT40) with the vaccinia microneutralization test (see above), we took advantage of the
193 greater specificity offered by the double-testing procedure as follows: we calculated an
194 "orthopoxviruses neutralization titer" (ONT) as the geometric mean of the vaccinia and
195 smallpox neutralization titers and considered samples with an ONT titer ≥ 20 to be positive.
196 Characteristics of the population studied according to age group and region are given in Table
197 3.

198 The global seroprevalence was 8.18%. It was over 10% in individuals born before
199 1970, dropped to 5% in those born during the 1970's, and to less than 1% after 1980. The
200 geometric mean of ONT in the complete sample was 12.8. We observed limited differences
201 according to age groups (Figure 1.a) but a clear overall increase of the proportion of positives
202 (Figure 1.b) in relation with age. Antibody titers and percentages of positives per decade are
203 given in figure 1.a and 1.b. The p-values of the tests comparing the neutralizing antibody
204 titers and the proportion of positives between each decade of birth are given in supplemental
205 Table 1.

206 The association between gender and antibodies neutralizing orthopoxviruses was
207 different depending on the decade of birth. Until the 1950s, seroprevalence was higher among
208 men, then balanced out in the 1960s and inverted in the 1970s when seroprevalence became
209 higher among women. From the 1980s onwards, as there are hardly any more positive
210 participants, no difference is observed (figure 1c. and 1d.).

211 The studied French sample geographically covers 4 regions: Auvergne-Loire (n=837
212 participants), Corsica (n=168), Midi-Pyrénées (n=1738) and PACA (n=1705). We compared
213 the different regions for each decade. We observed a few differences between these 4 regions
214 both in neutralizing antibodies titer and in percentages of positives (figures 1e. and 1f.).
215 Observed seroprevalence was higher in Corsica and in the Midi-Pyrénées region than in the
216 PACA region and especially the Auvergne-Loire region, which has the lowest seroprevalence
217 of the four regions for each decade of birth.

218 Finally, during the collection of samples, French participants filled in a detailed questionnaire
219 concerning lifestyle, eating habits, rurality index, contact with livestock or wild animals, etc.
220 We estimated the association between each of these parameters and ONT. Sixty parameters
221 were considered, and once the tests had been adjusted on age, none of the parameters were

222 found to influence seroprevalence. In short, in our study the only parameter directly
223 associated with the titer of orthopoxviruses neutralizing antibodies was age.

224

225 **Discussion**

226 With the end of smallpox vaccination in the 1980s, it was expected that the prevalence
227 of antibodies against orthopoxviruses would decline worldwide. Obviously, this
228 seroprevalence would decrease in the youngest (and never vaccinated) age groups, but it
229 could be assumed that the circulation of other orthopoxviruses would be responsible for the
230 development of immunity by natural infection in some individuals. Similarly, while it is
231 classically described that smallpox vaccination can produce long-lasting immunity, it could be
232 assumed that the immunosenescence of older vaccinated populations would contribute to a
233 decrease in seroprevalence in individuals vaccinated in childhood.

234 Consequently, the prevalence of anti-orthopoxvirus antibodies is difficult to anticipate
235 precisely in a given population because the parameters that can modulate it are numerous
236 (intensity of past vaccination campaigns, number of doses received, possible exposure to
237 infection by orthopoxviruses, factors modulating immunosenescence etc.). Our study allows
238 to provide concrete elements of seroprevalence and to compare several populations between
239 them. Nevertheless, it has several limitations, such as the non-representativeness of the
240 general population by the tested cohorts, obvious differences in the recruitment of participants
241 in the different international populations, the absence of individual vaccine data, the weakness
242 of the collected metadata, the limited number of elderly people tested and ultimately the
243 absence of a strict internationally validated threshold value for neutralization tests.

244 Looking at the overall picture of the data collected in the current study, it is broadly in
245 line with what was expected: seroprevalence is higher in countries that routinely vaccinated

246 and in participants born before the cessation of smallpox vaccination. However, when one
247 goes into more detail, a number of points deserve to be discussed.

248 The results in Laos and Bolivia are consistent with the previous WHO containment
249 strategy used when vaccination of the general population was not feasible. The seroprevalence
250 is remarkably low in Bolivia (<0.5%, whatever the threshold titer used) in both those born
251 before and after 1980. This reflects both likely low vaccination coverage and lack of exposure
252 to natural orthopoxvirus infection.

253 In Laos, the prevalence using a threshold titer of 40 (ThT40) is very low (<1%) but is
254 close to 4% with a threshold titer of 20 (ThT20). The prevalence values for individuals born
255 before 1980 are 1.75% (ThT40) and 7.02% (ThT20), compared with 0% and 2.67% for those
256 born after 1980. Therefore, neutralizing antibodies are found predominantly (but not
257 exclusively) in individuals born before 1980 and may be related to smallpox vaccination,
258 although a low-level exposure to orthopoxvirus infection cannot be formally excluded.

259 In Mali, the ThT40 seroprevalence is ~5% and rises to ~17% for ThT20. The
260 prevalence values for individuals born before 1980 are 10.71% (ThT40) and 27.68% (ThT20),
261 compared with 1.38% and 8.97% for those born after 1980. Since health authorities confirmed
262 that there was no smallpox vaccination campaign in the study area after 1980, the distribution
263 of seroprevalence in age groups presented in Supplemental Figure 1 for ThT20 suggests that
264 exposure to natural orthopoxvirus infection accounts for part of the observed immunity. This
265 is consistent with the fact that the samples were collected in villages located in a forested area
266 (southern Mali), and that circulation of monkeypox in humans, monkeys, and rodents has
267 been reported in central and western Africa for several decades, primarily at the edge of
268 forests(3). However, it is clear that vaccination may also explain the specifically high
269 prevalence in the oldest age groups in a proportion that we cannot determine.

270 In France, we had the opportunity to perform a double orthopox testing (vaccinia virus
271 and cowpox virus) in a large part of the population studied to improve the specificity of the
272 neutralization procedure. Results for both viruses were very similar (98% of participants had
273 concordant titers in both tests), confirming extensive cross-immunity within the orthopoxvirus
274 genus, which is well documented for smallpox, vaccinia and monkeypox viruses(27). We
275 found a global seroprevalence of 8.18%, which is mainly related to age (and thus to smallpox
276 vaccination coverage), with a sharp decline from the 1970s. We observed gender differences,
277 especially in the elderly, where it is higher in men (see Figure 1c. and 1d.). We assume that
278 the medical rigour resulting from military service for men in France may have played a role in
279 this age group.

280 In our study, we observed that some participants born in the early 1940s still have high
281 neutralization titers for orthopoxviruses. This is consistent with previous reports that smallpox
282 vaccination generates long-term splenic memory lymphocytes that can lead to the production
283 of anti-vaccine antibodies more than 80 years after vaccination(28–37). However, our results
284 also show a low seroprevalence among participants born before 1960 (~12.5%) compared to
285 the vaccination coverage estimated at 90% by Santé Publique France among people born
286 before 1966(20). These data suggest that individuals show, in proportions that are difficult to
287 define but higher than those suggested in the literature(34,38), a decrease in antibodies. To
288 what extent previously vaccinated individuals in whom no neutralizing antibody can be
289 detected retain any form of functional immunity against orthopoxviruses is unknown.

290 Our results also show that compliance with the smallpox vaccine or booster shots in
291 France had declined well before the end of compulsory vaccination with possible territorial
292 disparities. Smallpox had disappeared from Europe since the First World War and the
293 epidemics generated by imported cases in the 1950s(39,40) consistently suggest that

294 vaccination coverage had already begun to decline, driven by the adverse effects of the
295 vaccine.

296 Interestingly, ThT20 prevalence values in individuals born after 1980 are very low
297 (1.74% in Midi-Pyrénées, 0.65% in Auvergne-Loire and 0% in PACA), suggesting the
298 absence of natural orthopoxvirus infections. Further investigations and a larger number of
299 individuals tested are needed to decide on the case of Corsica where we identified a
300 proportion of individuals born after 1980 with antibodies to vaccinia virus. No environmental
301 factors were associated with seroprevalence in the French population despite a large database
302 on living conditions.

303 In conclusion, our study suggests that, overall, the different populations that we have
304 tested in Europe, Africa, Asia and South America are massively susceptible to orthopoxvirus
305 infections. Even in Africa, where there is significant evidence of natural circulation of
306 orthopoxviruses, population immunity is modest. Levels of protection are the lowest in
307 individuals born after 1980, due to the end of smallpox vaccination four decades ago. In
308 practical terms, this means that there is no population immunity to provide a barrier to the
309 spread of orthopoxviruses, and fully confirms that the cessation of smallpox vaccination may
310 facilitate the emergence of orthopoxvirus infections, as currently observed in the spread of
311 monkeypox virus in Europe.

312 **Biographical sketch**

313 Dr. Luciani is a pharmacist medical biologist working at Assistance Publique Hôpitaux de
314 Marseille and at the Unité des Virus Emergents, Aix Marseille Université, Marseille, France.
315 Her primary research interests include poxviruses and diagnostics of emerging viral
316 infections.

317 **Acknowledgments**

318 This work was supported by the European Union’s Horizon 2020 Research and Innovation
319 Programme under grant agreement 653316 (European Virus Archive goes global project:
320 <http://www.european-virus-archive.com/>). We are very grateful to the donors, and the staff of
321 the National Blood Transfusion Centre of the Lao Red Cross. We thank the staff of
322 Microbiology Laboratory, Mahosot Hospital, Dr Manivanh Vongsouvath (director), and Dr
323 Koukeo Phommasone (deputy director). We thank the staff of LOMWRU (Lao-Oxford-
324 Mahosot Hospital-Wellcome Trust-Research Unit), and Prof. Paul N Newton (former
325 director).

326 **Declaration of conflicting interests**

327 The author declares no conflict of interest.

328

329 **References**

- 330 1. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox
331 outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis* [Internet]. 2019
332 Oct 16 [cited 2020 Apr 15];13(10). Available from:
333 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816577/>
- 334 2. Doshi RH, Guagliardo SAJ, Doty JB, Babeaux AD, Matheny A, Burgado J, et al.
335 Epidemiologic and Ecologic Investigations of Monkeypox, Likouala Department,
336 Republic of the Congo, 2017. *Emerg Infect Dis*. 2019 Feb;25(2):281–9.
- 337 3. Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, et al.
338 Emergence of Monkeypox — West and Central Africa, 1970–2017. *MMWR Morb*
339 *Mortal Wkly Rep*. 2018 Mar 16;67(10):306–10.
- 340 4. Centers for Disease Control and Prevention (CDC). Update: multistate outbreak of
341 monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. *MMWR*
342 *Morb Mortal Wkly Rep*. 2003 Jun 27;52(25):589–90.
- 343 5. Vaughan A, Aarons E, Astbury J, Balasegaram S, Beadsworth M, Beck CR, et al. Two
344 cases of monkeypox imported to the United Kingdom, September 2018.
345 *Eurosurveillance* [Internet]. 2018 Sep 20 [cited 2019 Feb 8];23(38). Available from:
346 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.38.1800509>

- 347 6. Venkatesan G, Balamurugan V, Prabhu M, Yogisharadhya R, Bora DP, Gandhale PN, et
348 al. Emerging and re-emerging zoonotic buffalopox infection: a severe outbreak in
349 Kolhapur (Maharashtra), India. *Vet Ital.* 2010;46:10.
- 350 7. Kolhapure RM, Deolankar RP, Tupe CD, Raut CG, Basu A, Dama BM, et al.
351 Investigation of buffalopox outbreaks in Maharashtra State during 1992-1996. *Indian J*
352 *Med Res.* 1997 Nov;106:441-6.
- 353 8. Prabhu M. Camelpox and Buffalopox: Two Emerging and Re-emerging Orthopox Viral
354 Diseases of India. *Adv Anim Vet Sci.* 2015;3(10):527-41.
- 355 9. Balamurugan V, Venkatesan G, Bhanuprakash V, Singh RK. Camelpox, an emerging
356 orthopox viral disease. *Indian J Virol.* 2013 Dec 1;24(3):295-305.
- 357 10. Bera BC, Shanmugasundaram K, Barua S, Venkatesan G, Virmani N, Riyesh T, et al.
358 Zoonotic cases of camelpox infection in India. *Vet Microbiol.* 2011 Aug;152(1-2):29-
359 38.
- 360 11. Duraffour S, Mertens B, Meyer H, van den Oord JJ, Mitera T, Matthys P, et al.
361 Emergence of Cowpox: Study of the Virulence of Clinical Strains and Evaluation of
362 Antivirals. Tavis JE, editor. *PLoS ONE.* 2013 Feb 15;8(2):e55808.
- 363 12. Kurth A, Wibbelt G, Gerber HP, Petschaelis A, Pauli G, Nitsche A. Rat-to-Elephant-to-
364 Human Transmission of Cowpox Virus. *Emerg Infect Dis.* 2008 Apr;14(4):670-1.
- 365 13. Wolfs TFW, Wagenaar JA, Niesters HGM, Osterhaus ADME. Rat-to-Human
366 Transmission of Cowpox Infection. *Emerg Infect Dis.* 2002 Dec;8(12):1495-6.
- 367 14. Keesing F, Belden LK, Daszak P, Dobson A, Harvell CD, Holt RD, et al. Impacts of
368 biodiversity on the emergence and transmission of infectious diseases. *Nature.* 2010
369 Dec;468(7324):647-52.
- 370 15. Keesing F, Ostfeld RS. Impacts of biodiversity and biodiversity loss on zoonotic
371 diseases. *Proc Natl Acad Sci [Internet].* 2021 Apr 27 [cited 2021 Sep 16];118(17).
372 Available from: <https://www.pnas.org/content/118/17/e2023540118>
- 373 16. Schmeller DS, Courchamp F, Killeen G. Biodiversity loss, emerging pathogens and
374 human health risks. *Biodivers Conserv.* 2020 Oct 1;29(11):3095-102.
- 375 17. Berche P. The threat of smallpox and bioterrorism. *Trends Microbiol.* 2001 Jan
376 1;9(1):15-8.
- 377 18. Cohen J. BIOTERRORISM: Smallpox Vaccinations: How Much Protection Remains?
378 *Science.* 2001 Nov 2;294(5544):985-985.
- 379 19. Lane HC, Montagne JL, Fauci AS. Bioterrorism: A clear and present danger. *Nat Med.*
380 2001 Dec 1;7(12):nm1201-1271-1271.
- 381 20. Lévy-Bruhl D, Guérin N. Utilisation du virus de la variole comme arme biologique :
382 place de la vaccination en France. *Eurosurveillance.* 2001 Nov 1;6(11):171-8.

- 383 21. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID, Organization WH. Smallpox and
384 its eradication. Geneva: Geneva: World Health Organization; 1988.
- 385 22. Poinsignon A, Boulanger D, Binetruy F, Elguero E, Darriet F, Gallian P, et al. Risk
386 factors of exposure to *Aedes albopictus* bites in mainland France using an
387 immunological biomarker. *Epidemiol Infect* [Internet]. 2019 ed [cited 2021 Sep 13];147.
388 Available from: [https://www.cambridge.org/core/journals/epidemiology-and-](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/risk-factors-of-exposure-to-aedes-albopictus-bites-in-mainland-france-using-an-immunological-biomarker/45001FFB8F03EA609059592B005211DA)
389 [infection/article/risk-factors-of-exposure-to-aedes-albopictus-bites-in-mainland-france-](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/risk-factors-of-exposure-to-aedes-albopictus-bites-in-mainland-france-using-an-immunological-biomarker/45001FFB8F03EA609059592B005211DA)
390 [using-an-immunological-biomarker/45001FFB8F03EA609059592B005211DA](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/risk-factors-of-exposure-to-aedes-albopictus-bites-in-mainland-france-using-an-immunological-biomarker/45001FFB8F03EA609059592B005211DA)
- 391 23. Saba Villarroel PM, Nurtop E, Pastorino B, Roca Y, Drexler JF, Gallian P, et al. Zika
392 virus epidemiology in Bolivia: A seroprevalence study in volunteer blood donors. *PLoS*
393 *Negl Trop Dis*. 2018 Mar 7;12(3):e0006239.
- 394 24. Ninove L, Domart Y, Vervel C, Voinot C, Salez N, Raoult D, et al. Cowpox Virus
395 Transmission from Pet Rats to Humans, France. *Emerg Infect Dis*. 2009 May;15(5):781–
396 4.
- 397 25. Leparç-Goffart I, Poirier B, Garin D, Tissier MH, Fuchs F, Crance JM. Standardization
398 of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration
399 of vaccinia immunoglobulins and smallpox vaccines evaluation. *J Clin Virol*. 2005
400 Jan;32(1):47–52.
- 401 26. Lapidus N, Lamballerie X de, Salez N, Setbon M, Delabre RM, Ferrari P, et al. Factors
402 Associated with Post-Seasonal Serological Titer and Risk Factors for Infection with the
403 Pandemic A/H1N1 Virus in the French General Population. *PLOS ONE*. 2013 Apr
404 16;8(4):e60127.
- 405 27. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, et al.
406 Smallpox vaccine-induced antibodies are necessary and sufficient for protection against
407 monkeypox virus. *Nat Med*. 2005 Jul;11(7):740–7.
- 408 28. El-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, et al. The
409 Persistence of Neutralizing Antibodies after Revaccination against Smallpox. *J Infect*
410 *Dis*. 1990 Mar 1;161(3):446–8.
- 411 29. Demkowicz WE, Littau RA, Wang J, Ennis FA. Human cytotoxic T-cell memory:
412 long-lived responses to vaccinia virus. *J Virol*. 1996 Apr;70(4):2627–31.
- 413 30. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting Edge: Long-
414 Term B Cell Memory in Humans after Smallpox Vaccination. *J Immunol*. 2003 Nov
415 15;171(10):4969–73.
- 416 31. Pütz MM, Alberini I, Midgley CM, Manini I, Montomoli E, Smith GLY 2005.
417 Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. *J Gen*
418 *Virol*. 86(11):2955–60.
- 419 32. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al.
420 Duration of antiviral immunity after smallpox vaccination. *Nat Med*. 2003
421 Sep;9(9):1131–7.

- 422 33. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire F, et al.
423 Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN- γ -producing
424 T Cell Memory to Smallpox in Humans. *J Exp Med*. 2004 Jun 7;199(11):1585–93.
- 425 34. Taub DD, Ershler WB, Janowski M, Artz A, Key ML, McKelvey J, et al. Immunity
426 from Smallpox Vaccine Persists for Decades: A Longitudinal Study. *Am J Med*. 2008
427 Dec 1;121(12):1058–64.
- 428 35. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in
429 smallpox. *Bull World Health Organ*. 1975;52(3):307–11.
- 430 36. Amanna IJ, Carlson NE, Slifka MK. Duration of Humoral Immunity to Common Viral
431 and Vaccine Antigens. *N Engl J Med*. 2007 Nov 8;357(19):1903–15.
- 432 37. Mamani-Matsuda M, Cosma A, Weller S, Faili A, Staib C, Garçon L, et al. The human
433 spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. *Blood*.
434 2008 May 1;111(9):4653–9.
- 435 38. Anis E, Leventhal A, Slater PE, Shinar E, Yahalom V, Smetana Z, et al. Smallpox
436 revaccination of 21000 first responders in Israel: lessons learned. *Int J Infect Dis*. 2009
437 May 1;13(3):403–9.
- 438 39. Biraben JN. La diffusion de la vaccination en France au XIXe siècle. *Ann Bretagne Pays*
439 *Ouest*. 1979;86(2):265–76.
- 440 40. Le Boukdelles B. The Smallpox Epidemic of 1955 in France. *Bull Académie Natl*
441 *Médecine*. 1955;139(25/26):417–20.
- 442
- 443

444 **Tables**

	BOLIVIA	LAOS	MALI	FRANCE
Number of participants	601	657	255	4876
Sex ratio m/f	1.37	1.72	1.02	1.12
Year of birth ± sd	1989 ± 10	1985 ± 9	1980 ± 14	1967 ± 14
Participants born before 1960	3 (0.5%)	5 (0.8%)	26 (10%)	1560 (32%)
Participants born before 1980	161 (27%)	171 (26%)	112 (43%)	3826 (78%)
Neutralizing titer <20	598 (99.50%)	632 (96.19%)	211 (82.74%)	4137 (84.84%)
Neutralizing titer = 20	1 (0.17%)	22 (3.35%)	30 (11.76%)	425 (8.72%)
Neutralizing titer = 40	1 (0.17%)	3 (0.46%)	12 (4.71%)	217 (4.45%)
Neutralizing titer = 80	1 (0.17%)	0 (0.00%)	2 (0.78%)	86 (1.76%)
Neutralizing titer = 160	0 (0.00%)	0 (0.00%)	0 (0.00%)	11 (0.23%)
Overall seroprevalence ≥ 40	0.33%	0.46%	5.49%	6.44%
Overall seroprevalence ≥ 20	0.50%	3.81%	17.25%	15.16%

445
446
447
448
449
450
451

Table 1: Demographic characteristics and results of vaccinia virus neutralization in the 4 study populations.

		Antibodies neutralizing cowpox virus					452
		10	20	40	80	160	
Antibodies neutralizing vaccinia virus	10	3443 (77.44%)	407 (9.15%)	4 (0.09%)	2 (0.04%)	453 (0.02%)	
	20	234 (5.26%)	85 (1.91%)	12 (0.27%)	5 (0.11%)	454 (0.00%)	
	40	7 (0.16%)	77 (1.73%)	62 (1.39%)	12 (0.27%)	3 (0.07%)	
	80	0 (0.00%)	4 (0.09%)	31 (0.70%)	21 (0.47%)	3 (0.07%)	
	160	0 (0.00%)	1 (0.02%)	0 (0.00%)	2 (0.04%)	2 (0.04%)	

458 **Table 2:** Cross-reactivity between neutralizing assays of vaccinia virus and cowpox virus.

459
460
461

	CORSICA	MIDI-PYRENEES	PACA	AUVERGNE-LOIRE	TOTAL
SEX RATIO M/F	1.00	1.16	1.04	1.53	1.17
YEAR OF BIRTH ± SD	1966 ± 12	1966 ± 13	1967 ± 13	1966 ± 13	1966 ± 13
Participants born in the 1940s	14	185	162	77	438 (9.8%)
Participants born in the 1950s	38	443	371	213	1065 (23.9%)
Participants born in the 1960s	59	457	491	228	1235 (27.8%)
Participants born in the 1970s	33	308	359	166	866 (19.5%)
Participants born in the 1980s	21	244	252	106	623 (14.0%)
Participants born in the 1990s	3	101	70	47	221 (5.0%)
Total	168	1738	1705	837	4448

462

463 **Table 3:** Demographic characteristics of the French population tested with both vaccinia and
464 cowpox virus neutralization techniques. PACA: Provence Alpes Côte-d'Azur.

465

466 **Figure legend**

467 **Figure 1:** Results for the French population tested for both viruses (vaccinia and cowpox
468 virus). Overall comparison of ONT (a.) and percentage of positives (ONT > 20) (b.)
469 according to participants' decade of birth (p-values are in Supplemental Table 1). Comparison
470 for the same birth decade of the ONT (c.) and the percentage of positives (ONT > 20) (d.) by
471 gender of the participants (Mann-Whitney and Fischer tests, respectively). Comparison for the
472 same decade of ONT (e.) and percentage positive (ONT > 20) (f.) by living-region of
473 participants (Mann-Whitney and Fischer tests, respectively).

474

